One or more of the required application components couldn’t be loaded. Please, refresh the page.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
10:15 PM
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AAPG

Ascentage Pharma Group International ADR

Last Close
Mar 14 • 04:00PM ET
19.00
Dollar change
+0.37
Percentage change
1.99%
Healthcare • Biotechnology • China • NASD
AAPG - Stock Price Chart
AAPG - Short Interest, Short Float% Indicator
AAPG - Short Interest, Short Ratio Indicator

Short Interest History

Settlement DateShort InterestShares FloatAvg. Daily VolumeShort FloatShort Ratio
Feb 28, 2025141.34K-219.84K-0.64
Feb 14, 2025101.89K-298.21K-0.34
Jan 31, 202589.58K-497.71K-0.18
Scroll to Statements
Index- P/E- EPS (ttm)-0.70 Insider Own- Shs Outstand52.23M Perf Week-4.67%
Market Cap1.65B Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month6.44%
Income-49.71M PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales125.11M P/S13.16 EPS this Y- Inst Trans31.61% Short Ratio0.84 Perf Half Y-
Book/sh1.35 P/B14.09 EPS next Y- ROA-11.99% Short Interest0.14M Perf Year-
Cash/sh1.75 P/C10.87 EPS next 5Y- ROE-53.26% 52W Range16.50 - 21.40 Perf YTD9.32%
Dividend Est.- P/FCF- EPS past 5Y-11.77% ROI-20.79% 52W High-11.21% Beta-
Dividend TTM- Quick Ratio1.83 Sales past 5Y186.51% Gross Margin87.26% 52W Low15.15% ATR (14)0.85
Dividend Ex-Date- Current Ratio1.84 EPS Y/Y TTM63.29% Oper. Margin-37.93% RSI (14)51.31 Volatility3.68% 4.10%
Employees583 Debt/Eq2.22 Sales Y/Y TTM239.00% Profit Margin-39.73% Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq1.27 EPS Q/Q- Payout- Rel Volume0.14 Prev Close18.63
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMar 27 BMO Avg Volume168.12K Price19.00
SMA20-1.82% SMA501.32% SMA2001.32% Trades Volume24,359 Change1.99%
Mar-12-25 08:46AM
Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
(GlobeNewswire)
Mar-06-25 05:18PM
Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment
(Exec Edge)
Mar-05-25 06:00PM
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
(GlobeNewswire)
Feb-07-25 08:24AM
Ascentage Pharma Announces Partial Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
(GlobeNewswire)
Jan-28-25 04:01PM
Ascentage Pharma Announces Closing of U.S. Initial Public Offering
(GlobeNewswire)
Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Income Statement • Balance Sheet • Cash Flow

Data

Timeframe

PeriodTTMFY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period End Date—12/31/202312/31/202212/31/202112/31/202012/31/201912/31/201812/31/2017
Period Length12 Months12 Months12 Months

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, historical statements, and much more.

Learn more
Total Revenue
125.1131.3331.14
Cost of Goods Sold Incl. D&A
15.9415.2212.40
Gross Profit
109.1816.1118.75
Selling, General and Administrative Excl. Other
156.64142.01149.94
Research and Development
116.4295.11107.29
Other Operating Expense
0.000.000.00
Operating Income
-47.46-125.90-131.19
Interest Expense
10.7113.567.84
Unusual Expense
0.00-0.30-1.41
Net Income Before Taxes
-51.05-131.82-131.71
Income Taxes
-1.36-1.01-0.63
Consolidated Net Income
-49.74-130.66-131.12
Net Income From Continuing Operations
-49.71-130.65-131.12
Net Income
-49.71-130.65-131.12
EPS (Recurring)
-0.67-1.85-2.00
EPS (Basic, Before Extraordinaries)
-0.69-1.85-1.99
EPS (Diluted)
-0.70-1.85-1.99
EBITDA
-35.32-114.99-122.06
Price To Earnings Ratio
-26.98-26.98—
Price To Sales Ratio
———
Gross Margin
87.2651.4160.20
Operating Margin
-37.93-401.83-421.25
Net Margin
-39.73-416.98-421.02
Shares Outstanding
78.2372.5365.86
Market Capitalization
1,614.001,614.00—
values in Millions, USD
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.